Kinnate Biopharma Stock Current Ratio
| KNTEDelisted Stock | USD 2.96 0.27 8.36% |
Kinnate Biopharma fundamentals help investors to digest information that contributes to Kinnate Biopharma's financial success or failures. It also enables traders to predict the movement of Kinnate Stock. The fundamental analysis module provides a way to measure Kinnate Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kinnate Biopharma stock.
Kinnate |
Kinnate Biopharma Company Current Ratio Analysis
Kinnate Biopharma's Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Current Kinnate Biopharma Current Ratio | 23.30 X |
Most of Kinnate Biopharma's fundamental indicators, such as Current Ratio, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kinnate Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Typically, short-term creditors will prefer a high current ratio because it reduces their overall risk. However, investors may prefer a lower current ratio since they are more concerned about growing the business using assets of the company. Acceptable current ratios may vary from one sector to another, but the generally accepted benchmark is to have current assets at least as twice as current liabilities (i.e., Current Ration of 2 to 1).
CompetitionIn accordance with the recently published financial statements, Kinnate Biopharma has a Current Ratio of 23.3 times. This is much higher than that of the Biotechnology sector and 232.86% higher than that of the Health Care industry. The current ratio for all United States stocks is notably lower than that of the firm.
Kinnate Current Ratio Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kinnate Biopharma's direct or indirect competition against its Current Ratio to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Kinnate Biopharma could also be used in its relative valuation, which is a method of valuing Kinnate Biopharma by comparing valuation metrics of similar companies.Kinnate Biopharma is currently under evaluation in current ratio category among its peers.
Kinnate Fundamentals
| Return On Equity | -0.56 | |||
| Return On Asset | -0.34 | |||
| Current Valuation | (25.71 M) | |||
| Shares Outstanding | 47.17 M | |||
| Shares Owned By Insiders | 0.15 % | |||
| Shares Owned By Institutions | 82.58 % | |||
| Number Of Shares Shorted | 465.63 K | |||
| Price To Book | 0.79 X | |||
| EBITDA | (118.21 M) | |||
| Net Income | (112.65 M) | |||
| Cash And Equivalents | 262.42 M | |||
| Cash Per Share | 5.94 X | |||
| Total Debt | 3.17 M | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 23.30 X | |||
| Book Value Per Share | 3.66 X | |||
| Cash Flow From Operations | (100.04 M) | |||
| Short Ratio | 0.96 X | |||
| Earnings Per Share | (2.78) X | |||
| Target Price | 2.36 | |||
| Number Of Employees | 84 | |||
| Beta | 1.34 | |||
| Market Capitalization | 124.99 M | |||
| Total Asset | 173.6 M | |||
| Retained Earnings | (372.01 M) | |||
| Working Capital | 146.18 M | |||
| Z Score | 19.38 | |||
| Net Asset | 173.6 M |
About Kinnate Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kinnate Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kinnate Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kinnate Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Other Consideration for investing in Kinnate Stock
If you are still planning to invest in Kinnate Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kinnate Biopharma's history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Stocks Directory Find actively traded stocks across global markets |